Summary
Signal counts
Assets tracked: 2
Watchlist assets: 2
Registry stop assets: 0
Sponsor overview
Guangdong Provincial People's Hospital
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT06734182 | https://clinicaltrials.gov/study/NCT06547476
Assets
Linked programs
- Envafolimab injections+intravenous Disitamab Vedotin+carboplatin: Watchlist Signal (2/5)
- Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib: Watchlist Signal (2/5)